Commercial Capsules: Q2 Reporters, Mitsubishi Buy, Celltrion IPO, Renflexis Launch, Keytruda Fail, Ironwood and Vertex Trial Results
Executive Summary
Q2 reporting is on a roll as GSK unveils a major shake-up under new CEO Walmsley; the prospect of a simplified route to approval may have helped Neuroderm secure Mitsubishi take-out; biosimilar developments include Celltrion Healthcare's IPO and Merck & Co's launch of Renflexis in the US; clinical trial updates were reported for Keytruda, Ironwood's GERD candidate and Vertex's next generation of cystic fibrosis candidates. Commercial Capsules rounds up key commercial news reported recently by sister publication Scrip.
You may also be interested in...
Amgen Beats Consensus, Raises Earnings Guidance, But Is It Sustainable?
Amgen's second quarter beat consensus estimates, but with only a $100m increase in sales and few major growth drivers expected in the near term, earnings growth may not last.
Lilly Hopes To Revitalize Its Cancer Brand With 'Foundational' Agents
While reporting 19% US sales growth for the quarter, Lilly also outlined a revised oncology R&D strategy and revealed that refiling the NDA for baricitinib may be delayed 18 months or more.
Biogen's Neuroscience Strategy Includes De-Risking The Pipeline
Biogen is laser-focused on leading neuroscience, but management also talked about ways to balance the high-risk nature of competing in the challenging therapeutic area.